StockUnited StatesNasdaqGS

SYRE

Spyre Therapeutics, Inc.

Healthcare · Biotechnology

86.93USD

-3.8600 (-4.25%)

Description Historical Financials Relative Value Research News Discussion OptionsPrice Chart ↗Fundamental Chart ↗

Fiscal Year End12/2025

Last Quarter End06/2026 Q2

Current/T12M(USD)

Issue Data

Last PxUSD / 86.93

P/E—

Dvd Ind Yld—

P/B7.27

P/S—

Curr EV/T12M EBITDA—

Mkt Cap (USD)8.0B

Curr EV (USD)6.8B

Per Share Data

EPS T12M0.88

DPS—

Bk Val Per Sh10.84

Rev/Sh0.00

Cash/Sh12.99

Curr Shares Out88.2M

FCF/Sh-1.67

Cash Flow Analysis

P/CF-38.3

Curr P/FCF-94.3

CF/NI1.2

Dvd P/O0.0%

Cash Gen/Cash Reqd—

Csh Dvd Cov—

CFO/Sales—

Eff Interest Rate—

Growth Potential

Dil EPS 1Y Gr210.7%

Cap 1Y Gr38.1%

BPS 1Y Gr257.6%

R&D To Sales—

Retention Rate100.0%

Rev 1Y Gr—

FCF 1Y Gr-57.6%

Assets 1Y Gr27.8%

Profitability

EBITDA-0.2B

EBIT-0.2B

Operating Margin0.0%

Pretax Margin—

Net Margin0.0%

ROA-20.9%

ROE-23.0%

ROC-18.3%

Asset Turnover0.00

Structure

Current Ratio18.53

Quick Ratio18.23

Debt/Assets0.0%

Debt/Com Eq0.0%

Net Debt/EBITDA0.78

Tot Debt/Capital0.0%

Gross Margin0.0%

EBIT/Int Exp—

Returns and turnover use the AVERAGE balance over the year, not the closing snapshot. Growth rates compare the two most recent fiscal years.

Reading financial statements from SEC filings…

A first visit to a security takes a few seconds.